Koers Boule Diagnostics AB Nasdaq Stockholm
Aandelen
SE0000437402
Geavanceerde medische apparatuur & technologie
Omzet 2024 * | 584 mln. 53,85 mln. 50,04 mln. | Omzet 2025 * | 624 mln. 57,5 mln. 53,44 mln. | Marktkapitalisatie | 386 mln. 35,56 mln. 33,05 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 29 mln. 2,67 mln. 2,48 mln. | Nettowinst (verlies) 2025 * | 42 mln. 3,87 mln. 3,6 mln. | EV/omzet 2024 * | 0,79 x |
Nettoschuld 2024 * | 77,93 mln. 7,18 mln. 6,67 mln. | Nettoschuld 2025 * | 75,63 mln. 6,97 mln. 6,48 mln. | EV/omzet 2025 * | 0,74 x |
K/w-verhouding 2024 * |
13,3
x | K/w-verhouding 2025 * |
9,14
x | Werknemers | - |
Dividendrendement 2024 * |
2,06% | Dividendrendement 2025 * |
3,47% | Vrij verhandelbaar | 61,67% |
Recentste transcriptie over Boule Diagnostics AB
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Holger Lembrér
DFI | Director of Finance/CFO | - | 01/01 |
Aishat Bislieva
HRO | Human Resources Officer | - | 01-10-22 |
Fredrik Ekdahl
PRN | Corporate Officer/Principal | - | 01-01-12 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 71 | 01-01-21 | |
Chairman | 72 | 01-01-21 | |
Director/Board Member | 57 | 01-01-14 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+8,06% | 219 mld. | |
+6,94% | 183 mld. | |
+13,54% | 136 mld. | |
-3,73% | 63,07 mld. | |
+11,59% | 51,28 mld. | |
+7,76% | 52,55 mld. | |
+1,14% | 41,21 mld. | |
+3,21% | 36,43 mld. | |
+26,11% | 31,87 mld. |